STME (Stimcell Energetics) Cyclically Adjusted Revenue per Share: $0.00 (As of Feb. 2026)


STME Stimcell Energetics Inc STME
25 GF Score
Price $0.31
! 4 Warning Signs
View Full Analysis

What is Stimcell Energetics Cyclically Adjusted Revenue per Share?

Stimcell Energetics STME 25 Cyclically Adjusted Revenue per Share is $0.00 as of Feb. 2026. GuruFocus rates STME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Stimcell Energetics's adjusted revenue per share for the three months ended in Feb. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Feb. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-05), Stimcell Energetics's current stock price is $0.314. Stimcell Energetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2026 was $0.00. Stimcell Energetics's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Stimcell Energetics was 92.25. The lowest was 42.75. And the median was 60.00.


Stimcell Energetics  (OTCPK:STME) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Stimcell Energetics was 92.25. The lowest was 42.75. And the median was 60.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Stimcell Energetics Cyclically Adjusted Revenue per Share Related Terms


Stimcell Energetics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Stimcell Energetics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stimcell Energetics Cyclically Adjusted Revenue per Share Chart

Stimcell Energetics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.00 0.00 0.00

Stimcell Energetics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STME vs NVNO, TRIB, AIDX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Stimcell Energetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stimcell Energetics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Stimcell Energetics's Cyclically Adjusted PS Ratio falls into.


STME
25GF Score
Stimcell Energetics Inc STME
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stimcell Energetics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Stimcell Energetics's adjusted Revenue per Share data for the three months ended in Feb. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=0/131.0800*131.0800
=0.000

Current CPI (Feb. 2026) = 131.0800.

Stimcell Energetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201605 0.014 101.765 0.018
201608 0.002 101.686 0.003
201611 0.000 101.607 0.000
201702 0.000 102.476 0.000
201705 0.000 103.108 0.000
201708 0.000 103.108 0.000
201711 0.000 103.740 0.000
201802 0.000 104.688 0.000
201805 0.000 105.399 0.000
201808 0.000 106.031 0.000
201811 0.000 105.478 0.000
201902 0.000 106.268 0.000
201905 0.000 107.927 0.000
201908 0.006 108.085 0.007
201911 0.003 107.769 0.004
202002 0.002 108.559 0.002
202005 0.014 107.532 0.017
202008 0.000 108.243 0.000
202011 0.001 108.796 0.001
202102 0.001 109.745 0.001
202105 0.000 111.404 0.000
202108 0.000 112.668 0.000
202111 0.000 113.932 0.000
202202 0.000 115.986 0.000
202205 0.001 120.016 0.001
202208 0.000 120.569 0.000
202211 0.000 121.675 0.000
202302 0.000 122.070 0.000
202305 0.000 124.045 0.000
202308 0.000 125.389 0.000
202311 0.000 125.468 0.000
202402 0.000 125.468 0.000
202405 0.000 127.601 0.000
202408 0.000 127.838 0.000
202411 0.000 127.838 0.000
202502 0.000 128.786 0.000
202505 0.000 129.813 0.000
202508 0.000 130.210 0.000
202511 0.000 130.680 0.000
202602 0.000 131.080 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Stimcell Energetics (STME) has a Cyclically Adjusted Revenue per Share of $0.00 as of Feb. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stimcell Energetics and its competitors.
Is Stimcell Energetics' Cyclically Adjusted Revenue per Share too high?
Stimcell Energetics' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Stimcell Energetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' Cyclically Adjusted Revenue per Share compare to NVNO and TRIB?
Stimcell Energetics' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stimcell Energetics and its competitors. Stimcell Energetics's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Stimcell Energetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Stimcell Energetics (STME), the current Cyclically Adjusted Revenue per Share is $0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stimcell Energetics Business Description

Address 1130 Pender Street, West, Suite 820, Vancouver, BC, CAN, V6E 4A4
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
25GF Score

Get the complete analysis for STME

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price